Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

16 Oct 2008

Abstract excerpt

The BCL6 transcriptional repressor is the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs). BCL6 lymphomagenic activity is dependent on its ability to recruit corepressor proteins to a unique binding site on its N-terminal BTB domain. A recombinant peptide fragment of the SMRT (silencing mediator for retinoid and thyroid hormone receptor) corepressor that blocks this site can inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18927431
DOI: 10.1182/blood-2008-07-168773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoPMID 18927431Read ↗

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.Semantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read ↗

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomasSemantic proximity Read ↗

Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma CellsSemantic proximity Read ↗

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapySemantic proximity Read ↗

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and BeyondSemantic proximity Read ↗

BCL6 promotes glioma and serves as a therapeutic targetSemantic proximity Read ↗

Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.Semantic proximity Read ↗

Rewiring Cancer Drivers to Activate ApoptosisSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.